Serina Therapeutics, Inc. Income Tax Examination, Penalties and Interest Expense
Serina Therapeutics, Inc. (SER) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2026-03-25
- Serina Therapeutics, Inc. income tax examination, penalties and interest expense for fiscal 2025 was $0.00.
- Serina Therapeutics, Inc. income tax examination, penalties and interest expense for fiscal 2024 was $0.00.
- Serina Therapeutics, Inc. income tax examination, penalties and interest expense for fiscal 2023 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-25 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-25 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |